Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Johnson & Johnson: Q4 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2 per share. The world's biggest maker of health care products posted revenue of $22.52 billion in the period,
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the
Johnson & Johnson price target lowered to $155 from $170 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
The surprise position Ben Johnson says Bears can 'augment'
Whether Ben Johnson and Ryan Poles think it's a top priority isn't known but the new Bears coach threw out a position they could stand to 'augment.'
Opinion
FOX 321hOpinion
Column: Full of swagger, Ben Johnson is the right choice for the Chicago Bears. He knows it too
Ben Johnson doesn't need clichés to get his point across, nor does he want anything that he didn't earn. He's the right guy for the Chicago Bears. What's better is that he knows it, too.
WTTW2h
Johnson Brushes Off Threat of Arrest for Failing to Help Trump’s Mass Deportation Effort
We are not going to be intimidated by those acts of terror to radically shift our way of living,” Mayor Brandon Johnson said. “That’s what individuals who stoke fear into people want to see happen.”
Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring?
Shares of robotic surgery pioneer Intuitive Surgical (NASDAQ: ISRG) have been soaring lately. A preliminary look at sales results from the fourth quarter of 2024 suggests its business is on the right track.
Jessica Simpson shows ex what he's missing after 'painful' split
Pop star Jessica Simpson flaunted her toned legs and several jaw-dropping looks in a behind-the-scenes video from a photoshoot for her fashion collection.
Santa Rosa Press Democrat4h
Cracks emerge in House GOP after speaker's threat to saddle California wildfire aid with conditions
Some U.S. House Republicans in California are breaking with Speaker Mike Johnson over his suggestion that federal disaster aid be coupled with as-yet unspecified conditions on the wildfire-ravaged state.
Jim Cramer Likes Johnson & Johnson (JNJ) and the Kenvue Spin-Off – Here’s Why
We recently published a list of Jim Cramer Discusses TikTok Ban, President Trump & These 6 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses.